Wayne L G
Tubercolosis Research Laboratory, Department of Veterans Affairs Medical Centre, Long Beach, CA.
Methods Mol Med. 2001;54:247-69. doi: 10.1385/1-59259-147-7:247.
Great progress has been made in the latter half of the twentieth century in the understanding of the immunology of tuberculosis and of strategies for chemotherapeutic management of this disease. Indeed, given the evidence that the dominant, and perhaps sole, ecologic niche of Mycobacterium tuberculosis is the infected human host, it seemed reasonable to hope that the disease could not only be controlled, but eradicated by the end of this century (1). These hopes are dashed by the periodic resurgence of tuberculosis in various populations. Undoubtedly socioeconomic factors have played a major role in the failure to eradicate this disease, but another, neglected, factor is the apparent ability of the tubercle bacillus to remain in a relatively quiescent state in the host, neither replicating and causing progression of disease, nor dying off and disappearing from the host's tissues, in spite of apparently adequate immune responses and aggressive chemotherapy.
在20世纪后半叶,人们对结核病免疫学以及该疾病化疗管理策略的理解取得了巨大进展。事实上,鉴于有证据表明结核分枝杆菌的主要(或许也是唯一)生态位是受感染的人类宿主,人们有理由希望到本世纪末不仅能够控制这种疾病,而且能够根除它(1)。然而,结核病在不同人群中的周期性复发使这些希望破灭。毫无疑问,社会经济因素在未能根除这种疾病方面起了主要作用,但另一个被忽视的因素是结核杆菌在宿主体内明显能够保持相对静止的状态,尽管有明显足够的免疫反应和积极的化疗,它既不复制并导致疾病进展,也不死亡并从宿主组织中消失。